The efficacy and safety of once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus: A systemic review and meta-analysis

BACKGROUND: The efficacy and safety of once-weekly dipeptidyl peptidase-4 inhibitor (DPP-4i) omarigliptin as monotherapy or add on to other antihyperglycemic agents (AHAs) in patients with type 2 diabetes mellitus (T2DM) is unclear. METHODS: PubMed, EMBASE, Cochrane library, and ClinicalTrials.gov w...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xianying, Li, Xuejing, Qie, Suhui, Zheng, Yingying, Liu, Yang, Liu, Guoqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6112932/
https://www.ncbi.nlm.nih.gov/pubmed/30142816
http://dx.doi.org/10.1097/MD.0000000000011946

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6112932/
https://www.ncbi.nlm.nih.gov/pubmed/30142816
http://dx.doi.org/10.1097/MD.0000000000011946

Ejemplares similares